Currently, both the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) guidelines recommend testing for mutations in EGFR, BRAF, MET, NTRK and gene fusions (or rearrangements) in ALK, ROS1, RET and NTRK for all NSCLC tumors that contain an adenocarcinoma component, regardless of histologic grade, dominant histologic subtype, clinical characteristics or demographic information2,.3 The gene discussed is EGFR; the disease is adenocarcinoma.